Eisai Korea

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Eisai Korea sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Eisai Korea: 1 sponsored US clinical trial, 1 recruiting.

Eisai Korea sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Alzheimers Disease, with 1 trials.

Mid-pack sponsor footprint

Eisai Korea is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING

A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease

NCT06810960

Therapeutic Areas

Alzheimers Disease 1

What is open in the Eisai Korea pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Alzheimers Disease (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Eisai Korea: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Eisai Korea sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Eisai Korea1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Eisai Korea sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Eisai Korea sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Eisai Korea page

1 registered trials is a research-attention snapshot, not an endorsement of Eisai Korea or any single study.

  • 1 of Eisai Korea's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimers Disease is the condition Eisai Korea studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimers Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eisai Korea pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.